Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 April 2026, European Medicines Agency, Amsterdam, the Netherlands, from 7 April 2026 to 10 April 2026

Human medicines European public assessment report (EPAR): Opdualag, relatlimab,nivolumab, Date of authorisation: 15/09/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Adtralza, tralokinumab, Date of authorisation: 17/06/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Eurneffy, epinephrine, Date of authorisation: 22/08/2024, Revision: 5, Status: Authorised

Data protection and privacy at EMA

European Medicines Agency's data protection notice for the implementation of the Instrument for Pre-accession Assistance (IPA) programme

SPOR and XEVMPD status update webinar - Q2 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 April 2026, 10:00 (CEST) to 13 April 2026, 12:30 (CEST)

Industry Standing Group

Highlights - EMA - European Alliance of Associations for Rheumatology (EULAR) bilateral meeting - March 2026

Electronic application form (eAF) Q&A clinic, Online, European Medicines Agency, Amsterdam, the Netherlands, from 9 March 2026, 11:00 (CET) to 9 March 2026, 12:00 (CET)